Characteristic | Placebo/epoprostenol | Bosentan/epoprostenol |
Subjects n | 11 | 22 |
M:F | 5 (45):6 (55) | 5 (23):17 (77) |
Age yrs | 47±19 (15–68) | 45±17 (16–69) |
Weight kg | 78±16 (53–103) | 70±21 (40–109) |
Ethnic group | | |
Caucasian/White | 10 (91) | 18 (82) |
Black | 1 (9) | 1 (5) |
Asian | | 1 (5) |
Other | | 2 (9) |
Aetiology of PAH | | |
Primary | 10 (91) | 17 (77) |
Scleroderma | 1 (9) | 4(18) |
Systemic lupus erythematosus | | 1 (5) |
Modified NYHA functional class | | |
III | 8 (73) | 17 (77) |
IV | 3 (27) | 5 (23) |
Clinical signs of heart failure | 4 (36) | 10 (45) |
Concomitant PAH medications (only when >4 in at least one group) | | |
Antithrombotic agents | 10 (91) | 19 (86) |
High-ceiling diuretics | 10 (91) | 19 (86) |
Potassium sparing agents | 5 (45) | 14 (64) |
Cardiac glycosides | 2 (18) | 7 (32) |
Calcium channel blockers | 3 (27) | 6 (27) |
Use of supplemental oxygen | 4 (36) | 6 (27) |
Time since diagnosis months | 15±21 (1–61) | 13±30 (1–138) |